Is ARS Pharmaceuticals, Inc. (SPRY) a Buy, Sell, or Hold?
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$7.61 USD
-$0.13 (-1.68%)
- Volume
- 1.91M
- Average Volume
- 1.8M
- Market Capitalization
- $755.7M
- P/E Ratio
- -3.79
- Dividend Yield
- 0.00%
- Price Target
- $25.50
- Year High
- $18.63
- Year Low
- $6.66
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.94
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Richard E. Lowenthal |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | SPRY |
| CUSIP | 82835W108 |
| CIK | 0001671858 |
| Web | https://ars-pharma.com |
| Phone | 858 335 1300 |
| Currency | USD |
| Employees | 163 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.57 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.94 |
| Quick Ratio | 4.77 |
| Cash Ratio | 0.49 |
Sales & Book Value
| Annual Sales | $84.28M |
| Price / Sales | 7.63 |
| Cash Flow | -1.77 |
| Price / Cash Flow | -4.31 |
| Price / Book | 12.33 |
Price Target and Rating
| Average Stock Price Forecast | $25.50 |
| High Stock Price Forecast | $26.00 |
| Low Stock Price Forecast | $25.00 |
| Forecast Upside/Downside | -70.16% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.74 |
| Trailing P/E Ratio | -3.79 |
| PEG Ratio | 0.04 |
| P/E Growth | 0.04 |
| Net Income | $-171.3M |
| Net Margin | -200.00% |
| Pretax Margin | -200.08% |
| Return on Equity | -153.61% |
| Return on Assets | -68.84% |
Financials Score
| AltmanZ Score | -0.82 |
| Piotroski Score | 3.00 |
| Working Capital | 195.62M |
| Total Assets | 287.57M |
| Ebit | -195.62M |
| Market Cap | 752.65M |
| Total Liabilities | 226.26M |
Poll Results
About ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California. ...
2026-07-14 18:22:00
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-07-09 17:35:00
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. ("ARS" or the "Company") (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Can ARS Pharma's New CEO Unlock Neffy's Potential?
2026-07-09 13:37:56
On Tuesday, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) announced a leadership transition. Co-founder and CEO Richard Lowenthal stepped down as an employee and officer, effective July 6, 2026.
2026-07-07 17:38:00
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
ARS Pharmaceuticals Announces CEO Succession
2026-07-07 16:30:00
Richard Lowenthal, Chief Executive Officer, Transitioning following More than a Decade of Leadership Since Co-Founding the Company
ARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & Korsinsky
2026-07-06 14:00:00
ARS Pharmaceuticals stock lost more than 23% of its value in a single after-hours session after Neffy® failed to secure any new formulary additions in the July 2026 payer cycle -- a result that contradicted repeated executive coverage projections. NEW YORK, July 6, 2026 /PRNewswire/ -- Shareholders who held ARS Pharmaceuticals (NASDAQ: SPRY) stock watched more than 23% of their investment disappear on June 24, 2026, when the Company disclosed that Neffy® received zero new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle.
2026-07-01 10:07:00
NEW YORK--(BUSINESS WIRE)--Shareholders who held ARS Pharmaceuticals (NASDAQ: SPRY) stock watched the value drop more than 23% in after-hours trading on June 24, 2026, after the Company disclosed that Neffy® received no new commercial formulary additions or payer-coverage decisions in the July 1, 2026 review cycle. Investors who lost money on SPRY are encouraged to submit their information to discuss their legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.
2026-06-30 16:45:00
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or the “Company”) (NASDAQ: SPRY). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Frequently Asked Questions
-
What is the current ARS Pharmaceuticals, Inc. (SPRY) stock price?
-
ARS Pharmaceuticals, Inc.(NASDAQ:SPRY) stock price is $7.61 in the last trading session. During the trading session, SPRY stock reached the peak price of $18.63 while $6.66 was the lowest point it dropped to. The percentage change in SPRY stock occurred in the recent session was --1.68% while the dollar amount for the price change in SPRY stock was -$-0.13.
-
SPRY's industry and sector of operation?
-
The NASDAQ listed SPRY is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SPRY?
-
Justin Chakma | Chief Business Officer
Richard Lowenthal MSMSEL | Co-Founder, CEO & Director
Brian T. Dorsey | Chief Operations Officer
Donn Casale | President
Daniel Relovsky | Senior Vice President of Marketing -
How many employees does SPRY have?
-
Number of SPRY employees currently stands at 163. SPRY operates from 3525 Del Mar Heights Road, San Diego, CA 92130, US.
-
Link for SPRY official website?
-
Official Website of SPRY is: https://ars-pharma.com
-
How do I contact SPRY?
-
SPRY could be contacted at phone #858 335 1300 and can also be accessed through its website. SPRY operates from 3525 Del Mar Heights Road, San Diego, CA 92130, US.
-
How many shares of SPRY are traded daily?
-
The average number of SPRY shares traded daily for last 3 months was 1.8M.
-
What is the market cap of SPRY currently?
-
The market value of SPRY currently stands at $755.7M with its latest stock price at $7.61